Printer Friendly

Vifor Pharma announces three new clinical trials for Ferinject.

M2 PHARMA-July 12, 2017-Vifor Pharma announces three new clinical trials for Ferinject

(C)2017 M2 COMMUNICATIONS

Swiss pharmaceutical firm Vifor Pharma (SWX: GALE) has initiated three double-blind, placebo-controlled clinical trials to investigate the effects of Ferinject (ferric carboxymaltose) versus placebo on morbidity and mortality outcomes, the company reported on Wednesday.

The trials, titled AFFIRM-AHF, FAIR-HF2 and HEART-FID, come as part of the company's ongoing commitment to enhancing the lives of patients suffering from heart failure and iron deficiency.

The latest trials follow the FAIR-HF 1, CONFIRM-HF 2 and EFFECT-HF 3 trials, which previously demonstrated statistically significant beneficial effects of Ferinject in comparison to placebo or standard of care, in relation to symptoms, functional capacity and oxygen consumption, respectively.

Professor Piotr Ponikowski, head of the Department of Heart Diseases, Wroclaw Medical University and head of the Cardiology Department at the Centre for Heart Diseases at 4th Military Hospital, Wroclaw, Poland, and principle investigator for both the CONFIRM-HF and the AFFIRM-AHF trials, welcomed the news. He commented: "We are encouraged by the results of an analysis from the CONFIRM-HF trial which showed a reduction in hospitalisation for worsening heart failure in patients with systolic chronic heart failure and iron deficiency who were treated with Ferinject.

"This gives us reason to believe we may also be able to have a positive impact on vulnerable acute heart failure patients with iron deficiency and the AFFIRM-AHF trial sets out to prospectively study this."

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 12, 2017
Words:249
Previous Article:Wallace Named Chief Revenue Officer at PerfectServe.
Next Article:ERYTECH Pharma forms research collaboration with Queen's University to develop treatment for arginase-1 deficiency.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |